NASDAQ:CALT

Calliditas Therapeutics AB (publ) Stock Forecast, Price & News

$32.92

+1.34 (+4.24 %)

(As of 01/22/2021 12:00 AM ET)

Add

Compare

Today's Range

$32.03

Now: $32.92▼

$33.18

50-Day Range

$30.00

MA: $32.77▼

$34.74

52-Week Range

$19.00

Now: $32.92▼

$38.00

Volume6,284 shs

Average Volume17,177 shs

Market Capitalization$789.06 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Calliditas Therapeutics AB (publ) operates as a biopharmaceutical company in Stockholm, Sweden. It focuses on identifying, developing, and commercializing pharmaceutical products for patients with unmet medical needs. The company's lead product candidate is Nefecon, a unique formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy. Calliditas Therapeutics AB (publ) also intends to take Nefecon through a global Phase 3 study to commercialization. The company was founded in 2004 and is headquartered in Stockholm, Sweden.

Overall MarketRank^™

1.15 out of 5 stars

Medical Sector

875th out of 1,922 stocks

Pharmaceutical Preparations Industry

434th out of 769 stocks

2.5 Analyst's Opinion

Consensus Rating
Calliditas Therapeutics AB (publ) has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $38.00, Calliditas Therapeutics AB (publ) has a forecasted upside of 15.4% from its current price of $32.92.
Amount of Analyst Coverage
Calliditas Therapeutics AB (publ) has received no research coverage in the past 90 days.

2.6 Community Rank

Outperform Votes
Calliditas Therapeutics AB (publ) has received 10 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Calliditas Therapeutics AB (publ) has received 9 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Calliditas Therapeutics AB (publ) has received 52.63% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Calliditas Therapeutics AB (publ) and other stocks. Vote “Outperform” if you believe CALT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CALT will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Calliditas Therapeutics AB (publ) does not currently pay a dividend.
Dividend Growth
Calliditas Therapeutics AB (publ) does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Calliditas Therapeutics AB (publ) insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 11.85% of the stock of Calliditas Therapeutics AB (publ) is held by institutions.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Calliditas Therapeutics AB (publ) are expected to grow in the coming year, from ($1.81) to ($1.07) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Calliditas Therapeutics AB (publ) is -23.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Calliditas Therapeutics AB (publ) is -23.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:CALT

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.calliditas.se

Phone46-8411-3005

Employees23

Debt

Debt-to-Equity RatioN/A

Current Ratio23.46

Quick Ratio23.46

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$19.56 million

Price / Sales40.34

Cash FlowN/A

Price / Cash FlowN/A

Book ValueN/A

Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)($0.19)

Net Income$-3,450,000.00

Net MarginsN/A

Return on Equity-26.80%

Return on Assets-25.38%

Miscellaneous

Outstanding Shares23,969,000

Market Cap$789.06 million

Next Earnings Date2/12/2021 (Estimated)

OptionableNot Optionable

$32.92

+1.34 (+4.24 %)

(As of 01/22/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive CALT News and Ratings via Email

Sign-up to receive the latest news and ratings for CALT and its competitors with MarketBeat's FREE daily newsletter.

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Frequently Asked Questions

Is Calliditas Therapeutics AB (publ) a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Calliditas Therapeutics AB (publ) in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Calliditas Therapeutics AB (publ) stock.
View analyst ratings for Calliditas Therapeutics AB (publ) or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Calliditas Therapeutics AB (publ)?

Wall Street analysts have given Calliditas Therapeutics AB (publ) a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Calliditas Therapeutics AB (publ) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Calliditas Therapeutics AB (publ)'s next earnings date?

Calliditas Therapeutics AB (publ) is scheduled to release its next quarterly earnings announcement on Friday, February 12th 2021.
View our earnings forecast for Calliditas Therapeutics AB (publ).

How were Calliditas Therapeutics AB (publ)'s earnings last quarter?

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) released its quarterly earnings data on Thursday, November, 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.39) by $0.23.
View Calliditas Therapeutics AB (publ)'s earnings history.

What price target have analysts set for CALT?

4 brokerages have issued 1 year price objectives for Calliditas Therapeutics AB (publ)'s shares. Their forecasts range from $28.00 to $44.00. On average, they anticipate Calliditas Therapeutics AB (publ)'s share price to reach $38.00 in the next twelve months. This suggests a possible upside of 15.4% from the stock's current price.
View analysts' price targets for Calliditas Therapeutics AB (publ) or view Wall Street analyst' top-rated stocks.

Who are some of Calliditas Therapeutics AB (publ)'s key competitors?

Some companies that are related to Calliditas Therapeutics AB (publ) include I-Mab (IMAB), Rocket Pharmaceuticals (RCKT), ALX Oncology (ALXO), CytoDyn (CYDY), Nektar Therapeutics (NKTR), OPKO Health (OPK), Taro Pharmaceutical Industries (TARO), Pacira BioSciences (PCRX), Global Blood Therapeutics (GBT), IGM Biosciences (IGMS), Axsome Therapeutics (AXSM), Xencor (XNCR), Karuna Therapeutics (KRTX), Intra-Cellular Therapies (ITCI) and Deciphera Pharmaceuticals (DCPH).
View all of CALT's competitors.

What other stocks do shareholders of Calliditas Therapeutics AB (publ) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Calliditas Therapeutics AB (publ) investors own include Ampio Pharmaceuticals (AMPE), Trevena (TRVN), Advanced Micro Devices (AMD), ChromaDex (CDXC), Chimerix (CMRX), CorMedix (CRMD), CTI BioPharma (CTIC), DRDGOLD (DRD), (EQX) and Forte Biosciences (FBRX).

Who are Calliditas Therapeutics AB (publ)'s key executives?

Calliditas Therapeutics AB (publ)'s management team includes the following people:

Ms. Renee Aguiar-Lucander, Chief Exec. Officer (Age 59)
Mr. Mikael Bender, Co-Founder
Mr. Fredrik Johansson, Chief Financial Officer (Age 44)
Ms. Katayoun Welin-Berger, VP Operations (Age 53)
Dr. Johan Haggblad, Chief Scientific Officer (Age 63)
Mr. Mikael Widell, Head of Communications & IR (Age 63)
Mr. Jonathan A. Schur, Group Gen. Counsel
Ms. Ann-Kristin Myde, Head of Clinical Devel. & VP of Project Management (Age 66)
Mr. Andrew Udell B.Sc., M.B.A., Head of North America, Commercial (Age 51)
Dr. Krassimir Mitchev, Head of Medical Affairs (Age 62)

When did Calliditas Therapeutics AB (publ) IPO?

(CALT) raised $179 million in an initial public offering (IPO) on Friday, June 5th 2020. The company issued 9,200,000 shares at $19.50 per share. Citigroup, Jefferies and Stifel acted as the underwriters for the IPO and Carnegie was co-manager.

What is Calliditas Therapeutics AB (publ)'s stock symbol?

Calliditas Therapeutics AB (publ) trades on the NASDAQ under the ticker symbol "CALT."

When did Calliditas Therapeutics AB (publ)'s lock-up period expire?

Calliditas Therapeutics AB (publ)'s lock-up period expired on Wednesday, December 2nd. Calliditas Therapeutics AB (publ) had issued 4,153,385 shares in its public offering on June 5th. The total size of the offering was $80,991,008 based on an initial share price of $19.50. Since the expiration of Calliditas Therapeutics AB (publ)'s lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company have been lifted.

How do I buy shares of Calliditas Therapeutics AB (publ)?

Shares of CALT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Calliditas Therapeutics AB (publ)'s stock price today?

One share of CALT stock can currently be purchased for approximately $32.92.

How big of a company is Calliditas Therapeutics AB (publ)?

Calliditas Therapeutics AB (publ) has a market capitalization of $789.06 million and generates $19.56 million in revenue each year. The company earns $-3,450,000.00 in net income (profit) each year or ($0.19) on an earnings per share basis. Calliditas Therapeutics AB (publ) employs 23 workers across the globe.

What is Calliditas Therapeutics AB (publ)'s official website?

The official website for Calliditas Therapeutics AB (publ) is www.calliditas.se.

How can I contact Calliditas Therapeutics AB (publ)?

Calliditas Therapeutics AB (publ)'s mailing address is KUNGSBRON 1 C8, STOCKHOLM V7, 11122. The company can be reached via phone at 46-8411-3005 or via email at [email protected]

This page was last updated on 1/23/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here